By FSD Pharma on Monday, 10 August 2020
Category: Vertically Integrated

FSD Pharma says $10M in new capital is 'gratifying' as the firm makes progress in coronavirus trial

viewFSD Pharma

Inc (NASDAQ:HUGE) () CEO Raza Bokhari tells Proactive it has closed US$10 million in a registered direct offering.

Bokhari says the offering comes as the Canadian company actively works to submit an Investigational New Drug Application to the FDA to use its FSD201 as a possible treatment to reduce lung inflammation in hospitalized coronavirus patients.

CSE:HUGE

Market: CSE
Market Cap: $40.78 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

FSD Pharma raises more than C$10M in private placement, makes progress with...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive how the firm is planning to use its recently-raised C$10.125 million. Bokhari says the Cobourg, Ontario-headquartered company had struck agreements with institutional investors for the purchase and sale of 1.5 million of...

on 06/12/2020

2 min read

Related Posts